Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 97 for “"multiple myeloma"”.
-
Immunotherapy in multiple myeloma
The BDCA antibodies allowed reliable measurement of dendritic cell (DC) subsets and B cell numbers in the blood of normal subjects, and patients with MM throughout the disease course. The numbers of blood myeloid DC (BmDC) and blood plasmacytoid DC (BpDC) are low throughout the course of the …
-
biological treatment options of multiple myeloma
Multiple myeloma encompasses 10% of hematological malignancies and is characterised by end organ damage and the presence of bone lesions. Currently, myeloma therapies involve the use of combinations of multiple agents from various classes. These include proteosome inhibitors, monoclonal antibodies, …
-
Cell-Free Dna Sequencing In Multiple Myeloma
<p>Multiple myeloma (MM) is an incurable plasma cell dyscrasia. Recent advances in MM therapy, including CAR-T therapy, have increased survival and shown the value of assessing treatment response with great sensitivity, both in acute and long-term settings. Cell-free DNA, DNA fragments which are …
-
The Role of Gremlin1 in Multiple Myeloma
Multiple myeloma (MM) is a fatal haematological malignancy characterised by the clonal proliferation of malignant plasma cells (PC) within the bone marrow (BM). In most instances, MM PCs are reliant on factors made by cells of the BM stroma for their survival and growth. To date, the nature and …
-
Genetic changes in the development of multiple myeloma
Multiple myeloma (MM) is a malignancy of clonal plasma cells (PC) which develops as a consequence of a multistep process of transformation from a normal PC to an asymptomatic stage known as monoclonal gammopathy of undetermined significance (MGUS) to MM to the more aggressive plasma cell leukaemia …
-
Enhancement of death receptor-mediated apoptosis in multiple myeloma cells
Background: Multiple Myeloma (MM) is currently incurable despite many novel therapies. Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is a potential anti-tumour agent although the effects as a single agent are limited. This investigation determined whether the Histone Deacetylase …
-
CD166 modulates disease progression and osteolytic disease in multiple myeloma
Multiple myeloma (MM) is an incurable malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow (BM) and by multiple osteolytic lesions throughout the skeleton. We previously reported that CD166 is a functional molecule on normal hematopoietic stem cells (HSC) that …
-
Defining the functional role of MAGE-C1 in Multiple Myeloma
… antigens (CTAs) in various cancers, including multiple myeloma, makes them attractive targets for therapy and biomarker development. Despite intensive studies, their potential has not been fully realized due to lack of knowledge regarding their pathogenic role. To start elucidating the function …
-
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
… thesis was to evaluate the mechanisms whereby myeloma cells develop intrinsic resistance with a focus on resistance in the context of bortezomib treatment. The aims of this thesis were to examine multidrug resistance pumps as a mechanism of resistance in MM, to investigate the contribution of …
-
role of NF-<i>k</i>B signaling in multiple myeloma
<p>Genomic DNA was purified from Multiple Myeloma Cell Line JJN3, and BMF promoter region was PCR amplified and cloned into pCR 2.1 TOPO vector using One Shot® Chemically Competent E. coli. After confirmation of the clone through polymerase chain reaction (PCR) and restriction analysis, BMF …
-
DISSECTING THE CLINICAL AND BIOLOGICAL RELEVANCE OF DIS3 GENE IN MULTIPLE MYELOMA
Multiple myeloma (MM) is a B cell malignancy characterized by abnormal proliferation of plasma cells (PCs) within the bone marrow. MM is characterized by a wide clinical spectrum ranging from the presumed asymptomatic pre-malignant condition called monoclonal gammopathy of undetermined significance …
-
Multiple Myeloma and Its Treatment Alter Peripheral Nervous System Structure and Function
<p><strong>MULTIPLE MYELOMA AND ITS TREATMENT ALTER PERIPHERAL NERVOUS SYSTEM STRUCTURE AND FUNCTION </strong></p> <p>Alyssa Katarina Kosturakis, BA</p> <p>Supervisory Professor: Patrick M. Dougherty, PhD</p> <p>Peripheral neuropathy is among the most deleterious side effects of frontline …
-
Cross-Presentation Is A Source of Tumor Antigens For Multiple Myeloma Immunotherapy
… antigens. We therefore hypothesized that multiple myeloma would be capable of cross-presentation as these cells are derived from B cells, known APCs. We explored the capacity of multiple myeloma to cross-present PR1, a human leukocyte antigen (HLA)-A2 nonameric peptide that is derived from …
-
Myeloma-osteoclast interactions as a therapeutic target for multiple myeloma bone disease
<p>Multiple myeloma (MM) is a cancer of terminally differentiated B lymphocytes, also known as plasma cells, which are cells specialized in generating antibodies. MM is responsible for 35,000 diagnoses and 13,000 deaths in the US annually. While both malignant and non-malignant plasma cells …
Page 1 of 5